Edmond Paquette, MD
Urology · Fairfax, VANPI 1851356034
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $2,636 of the $3,713 with a category attached, or 71.0%. Boston Scientific accounts for 65.8% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2024 at $2,310 and has fallen 93.8% since, to $144 in 2025.
Across 20 payments — averaging $185.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Procept Biorobotics Corporation$1K
- Smith+Nephew$20
- AbbVie$13
What the payments were for
- Travel & lodging$2,63671%
- Food & beverage$1,05828%
- Education$201%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 10 | $2,445 |
| Procept Biorobotics Corporation | 8 | $1,236 |
| Smith+Nephew | 1 | $20 |
| AbbVie | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AquaBeam Robotic System$1,140
- REZUM$135
How this compares
$3,713 in reported general payments places this provider in the 55th percentile of 300 urology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 25 | $32,782 |
| GemtesaVibegron | 14 | $11,513 |
| Testosterone | 33 | $7,226 |
| Trospium Chloride | 44 | $4,495 |
| Tamsulosin Hcl | 271 | $4,375 |
| Potassium Citrate ErPotassium Citrate | 21 | $3,754 |
| Alfuzosin Hcl ErAlfuzosin Hcl | 177 | $3,400 |
| Finasteride | 219 | $2,821 |
| Solifenacin Succinate | 47 | $2,566 |
| Tolterodine Tartrate ErTolterodine Tartrate | 16 | $1,970 |
| Desmopressin Acetate | 15 | $1,859 |
| Methenamine Hippurate | 13 | $1,036 |
| Dutasteride | 32 | $684 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 17 | $654 |
| Oxybutynin Chloride | 28 | $595 |
Paid to pharmacies, not to this prescriber.
Other urology in Fairfax
- Simon ChungFairfax$12K
- Michael FabrizioVirginia Beach$1.5M
- Gregg EureVirginia Beach$1.4M
- Jessica DelongVirginia Beach$578K
- Robert GivenVirginia Beach$157K
- Michael WilliamsVirginia Beach$144K
- Nilay GandhiWoodbridge$138K
- Shawn MarhamatiWoodbridge$130K
- Patrick WhelanSuffolk$114K
- Jennifer Miles-ThomasVa Beach$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.